Development of NK3R Antagonists with a Degradable Scaffold in the Natural Environment: Synthesis and Application of Fused Piperazine Derivatives for Investigation of Degradable Core Motifs
Publisher
Springer Singapore
Reference53 articles.
1. (a) Hoveyda HR, Fraser GL, Roy M, Dutheuil G, Batt F, Bousmaqui MEl, Korac J, Lenoir F, Lapin A, Blanc S (2015) Discovery and optimization of novel antagonists to the human neurokinin‑3 receptor for the treatment of sex-hormone disorders (Part I). J Med Chem 58:3060-3082.
2. (b) Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, Lapin A, Noël S (2015) Optimization of novel antagonists to the neurokinin‑3 receptor for the treatment of sex-hormone disorders (Part II). ACS Med Chem Lett 6:736-740
3. (a) Fraser GL, Hoveyda HR, Clarke IJ, Ramaswamy S, Plant TM, Rose C, Millar RP (2015) The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian hormones throughout the menstrual cycle. Endocrinology 156:4214-4225.
4. (b) Fraser GL, Ramael S, Hoveyda HR, Gheyle L, Combalbert J (2016) The NK3 receptor antagonist ESN364 suppresses sex hormones in men and women. J Clin Endocrinol Metab 101:417-426.
5. (c) Skorupskaite K, George JT, Veldhuis J, Millar RP, Anderson RA (2018) Neurokinin 3 receptor antagonism reveals roles for neurokinin B in the regulation of gonadotropin secretion and hot flashes in postmenopausal women. Neuroendocrinology 106:148-157